US panel backs first-of-a-kind Covid-19 pill from Merck
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Monday
August 15, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
MONDAY, AUGUST 15, 2022
US panel backs first-of-a-kind Covid-19 pill from Merck

Coronavirus chronicle

Reuters
01 December, 2021, 10:05 am
Last modified: 01 December, 2021, 10:09 am

Related News

  • Angry China stages more drills near Taiwan as US lawmakers visit
  • Philippines in talks to buy US helicopters after dropping Russia deal
  • Biden calls India an 'indispensable partner' on 75th anniversary of independence
  • Iranian nuclear deal limbo may serve interests of both US and Iran
  • Wall Street revives Russian bond trading after US go-ahead

US panel backs first-of-a-kind Covid-19 pill from Merck

The FDA isn’t bound by the panel’s recommendation and is expected to make its own decision before year’s end. The antiviral is already authorized in the UK

Reuters
01 December, 2021, 10:05 am
Last modified: 01 December, 2021, 10:09 am
Photo :Collected
Photo :Collected

A panel of US health advisers on Tuesday narrowly backed a closely watched Covid-19 pill from Merck, setting the stage for a likely authorization of the first drug that Americans could take at home to treat the coronavirus.

The Food and Drug Administration panel voted 13-10 that the antiviral drug's benefits outweigh its risks, including potential birth defects if used during pregnancy.

"I see this as an incredibly difficult decision with many more questions than answers," said panel chair Dr. Lindsey Baden of Harvard Medical School, who voted in favor of the drug. He said FDA would have to carefully tailor the drug's use for patients who stand to benefit most.

The recommendation came after hours of debate about the drug's modest benefits and potential safety issues. Most experts backing the treatment stressed that it should not be used by anyone who is pregnant and called on FDA to recommend extra precautions before the drug is prescribed, such as pregnancy tests for women of child-bearing age.

The vote specifically backed the drug for adults with mild-to-moderate Covid-19 who face the greatest risks, including older people and those with conditions like obesity and asthma. Most experts also said the drug shouldn't be used in vaccinated people, who weren't part of Merck's research and haven't been shown to benefit.

The FDA isn't bound by the panel's recommendation and is expected to make its own decision before year's end. The antiviral is already authorized in the UK

The drug, molnupiravir, could provide a much-needed weapon against the virus as colder weather pushes case counts higher and US officials brace for the arrival of the new omicron variant.

Merck hasn't specifically tested its drug against the new variant but said it should have some potency based on its effectiveness against other strains of coronavirus.

That uncertainty frustrated many panelists as they grappled with whether to back the treatment for millions of Americans.

"With no data saying it works with new variants, I really think we need to be careful about saying that this is the way to go," said Dr. David Hardy of Charles Drew University School of Medicine and Science, who ultimately voted to back the drug.

On Friday, Merck released updated data that paint a less compelling picture of the drug's effectiveness than just a few weeks earlier.

Merck said final study results showed molnupiravir reduced hospitalization and death by 30% among adults infected with the coronavirus, when compared with adults taking a placebo. That effect was significantly less than the 50% reduction it first announced based on incomplete results.

For many panelists, the modest effect wasn't enough to outweigh the drug's potential toxicity to human fetuses.

"Given the large potential population affected, the risk of widespread effects on potential birth defects has not been adequately studied," said Dr. Sankar Swaminathan of the University of Utah School of Medicine, who voted against the drug.

FDA scientists told the panelists earlier Tuesday that company studies in rats showed the drug caused birth defects when given at very high doses. FDA staffers concluded the data "suggest that molnupiravir may cause fetal harm when administered to pregnant individuals."

The agency is weighing a blanket restriction against any use in pregnant women or allowing doctors to use the drug in rare cases. Some panelists said that option should be left open for pregnant mothers who have high-risk Covid-19 and may have few other treatment options.

Dr. Janet Cragan, who backed the drug, said that even with tight restrictions some pregnant women would inevitably take the antiviral.

"I don't think you can ethically tell a woman with Covid-19 that she can't have the drug if she's decided that's what she needs," said Cragan, a panel member and staffer with the Centers for Disease Control and Prevention. "I think the final decision has to come down to the individual woman and her provider."

Merck's drug uses a novel approach to fight Covid-19: It inserts tiny errors into the coronavirus' genetic code to stop it from reproducing. That genetic effect has raised concerns that the drug could spur more virulent strains of the virus. FDA regulators said Tuesday that risk is theoretical but many panelists said it should be carefully tracked in follow-up studies.

Antiviral pills have long been seen as a key advance beyond currently used antibody drugs, which must be injected or infused by health professionals. But given the shortcomings of Merck's data, several experts said they would prioritize patients to receive the older drugs.

While Merck and its partner Ridgeback Biotherapeutics were the first to submit their Covid-19 pill to the FDA, rival drugmaker Pfizer is close behind with its own pill under review.

Pfizer's drug is part of a decades-old family of antiviral pills known as protease inhibitors, a standard treatment for HIV and hepatitis C. They work differently than Merck's pill and haven't been linked to the kind of mutation concerns raised with Merck's drug.

Pfizer said this week that its drug shouldn't be affected by the omicron variant's mutations.

Both drugs require patients to take multiple pills, twice a day for five days.

The US government has agreed to purchase 10 million treatment courses of Pfizer's drug, if it's authorized. That's more than three times the government's purchase agreement with Merck for 3.1 million courses of molnupiravir.

Top News / World+Biz

US / covid 19 pill / Merck

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Chawkbazar fire: Six bodies found from restaurant
    Chawkbazar fire: Six bodies found from restaurant
  • Bangladesh may get annual fixed quota for food imports from India
    Bangladesh may get annual fixed quota for food imports from India
  • Illustration: TBS
    His presence felt everywhere

MOST VIEWED

  • Southern hemisphere to get first mRNA vaccine facility
    Southern hemisphere to get first mRNA vaccine facility
  • North Korea's leader Kim Jong Un greets health workers and scientists struggling with the coronavirus disease (Covid-19) pandemic during a photo session in Pyongyang, North Korea, in this undated photo released on August 10, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS
    North Korea lifts mask mandate, distancing rules after declaring Covid victory
  • A motorist passes by a mural of frontline workers against coronavirus at RK Puram in New Delhi on July 25. Delhi’s Covid-19 recoveries have outstripped new cases on almost all days this month barring a few exceptions, after ramped-up containment and testing efforts over the past month or so. (Sanchit Khanna / HT Photo)
    Delhi to enforce mask mandate again after spurt in Covid cases
  • A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell
    US CDC no longer recommends students quarantine for Covid-19 exposure
  • In this file photo taken on March 2, 2019, Kim Yo Jong, sister of North Korea's leader Kim Jong Un, attends a wreath-laying ceremony at Ho Chi Minh Mausoleum in Hanoi. Photo: Hindustan Times
    Kim Jong Un's sister warns Seoul of 'retaliation' over Covid
  • North Korean leader Kim Jong Un speaks at a politburo meeting of the Worker's Party on the country's coronavirus disease (COVID-19) outbreak response in this undated photo released by North Korea's Korean Central News Agency (KCNA) on May 21, 2022. KCNA via REUTERS
    North Korea declares victory over Covid, suggests leader Kim had it

Related News

  • Angry China stages more drills near Taiwan as US lawmakers visit
  • Philippines in talks to buy US helicopters after dropping Russia deal
  • Biden calls India an 'indispensable partner' on 75th anniversary of independence
  • Iranian nuclear deal limbo may serve interests of both US and Iran
  • Wall Street revives Russian bond trading after US go-ahead

Features

The macabre multicide: How we failed our supreme leader

The macabre multicide: How we failed our supreme leader

3h | Supplement
Bangabandhu Sheikh Mujibur Rahman with his eldest daughter Sheikh Hasina and his grandson Sajeeb Wazed at his Dhanmondi residence. Photo: Achieve

The darkest night of 15 August

4h | Supplement
As long as the Padma and the Meghna will flow…

As long as the Padma and the Meghna will flow…

5h | Supplement
Baah: A sustainable way to upgrade your home

Baah: A sustainable way to upgrade your home

6h | Brands

More Videos from TBS

Forest Department takes initiative to protect wildlife in Purbachal

Forest Department takes initiative to protect wildlife in Purbachal

5h | Videos
Bangabandhu's humane values

Bangabandhu's humane values

5h | Videos
Why trolling happens on personal matter

Why trolling happens on personal matter

5h | Videos
House that reveals story of Bangladesh

House that reveals story of Bangladesh

5h | Videos

Most Read

1
Dollar crisis: BB orders removal of 6 banks’ treasury chiefs 
Banking

Dollar crisis: BB orders removal of 6 banks’ treasury chiefs 

2
From left Afzal Karim, Murshedul Kabir and Mohammad Jahangir
Banking

Sonali, Agrani and Rupali banks get new MDs

3
Photo: Collected
Transport

Will Tokyo’s traffic model solve Dhaka’s gridlocks?

4
Representational Image. Photo: Collected
Bangladesh

Air passengers should plan extra commute time to airport: DMP

5
Arrest warrant against Habib Group chairman, 4 others 
Crime

Arrest warrant against Habib Group chairman, 4 others 

6
Ambassador of Switzerland to Bangladesh Nathalie Chuard. Photo: Courtesy
Bangladesh

Bangladesh never asked for particular info from Swiss bank: Ambassador

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net